ACADIA Pharmaceuticals Inc. EPS (Earnings per Share) 2009–2025
ACADIA Pharmaceuticals Inc. reported $2.30 of earnings per share for fiscal 2025. That was 69.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +228.5%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2025 | $2.30 | +69.1% |
| FY 2024 | $1.36 | +467.6% |
| FY 2023 | $-0.37 | +72.4% |
| FY 2022 | $-1.34 | -27.6% |
| FY 2021 | $-1.05 | +41.3% |
| FY 2020 | $-1.79 | — |
| FY 2019 | $0.00 | — |
| FY 2018 | $0.00 | — |
| FY 2017 | $0.00 | — |
| FY 2016 | $0.00 | — |
| FY 2015 | $0.00 | — |
| FY 2014 | $0.00 | — |
| FY 2013 | $0.00 | +100.0% |
| FY 2012 | $-0.38 | +13.6% |
| FY 2011 | $-0.44 | -212.8% |
| FY 2010 | $0.39 | +132.5% |
| FY 2009 | $-1.20 | — |
Source: ACADIA Pharmaceuticals Inc. SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ACAD 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
ACADIA Pharmaceuticals Inc. reported $2.30 of earnings per share for fiscal 2025. That was 69.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +228.5%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for ACADIA Pharmaceuticals Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeACADIA Pharmaceuticals Inc. — frequently asked questions
What is ACADIA Pharmaceuticals Inc.'s earnings per share?
ACADIA Pharmaceuticals Inc. (ACAD) reported earnings per share of $2.30 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from ACADIA Pharmaceuticals Inc.'s official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.